TrialCancer2022

Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.

Alessio Cortellini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.